Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up

Mostrar otras versiones (1)
Detalles Bibliográficos
Autores principales: Dori, Amir, Guglieri, Michela, Scutifero, Marianna, Passamano, Luigia, Trabacca, Antonio, Politano, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore Srl 2022
Materias:
Retraction Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299955/
https://www.ncbi.nlm.nih.gov/pubmed/35919205
_version_ 1784751097650348032
author Dori, Amir
Guglieri, Michela
Scutifero, Marianna
Passamano, Luigia
Trabacca, Antonio
Politano, Luisa
author_facet Dori, Amir
Guglieri, Michela
Scutifero, Marianna
Passamano, Luigia
Trabacca, Antonio
Politano, Luisa
author_sort Dori, Amir
collection PubMed
description
format Online
Article
Text
id pubmed-9299955
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Pacini Editore Srl
record_format MEDLINE/PubMed
spelling pubmed-92999552022-08-01 Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up Dori, Amir Guglieri, Michela Scutifero, Marianna Passamano, Luigia Trabacca, Antonio Politano, Luisa Acta Myol Retraction Statement Pacini Editore Srl 2022-06-30 /pmc/articles/PMC9299955/ /pubmed/35919205 Text en ©2022 Gaetano Conte Academy - Mediterranean Society of Myology https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en
spellingShingle Retraction Statement
Dori, Amir
Guglieri, Michela
Scutifero, Marianna
Passamano, Luigia
Trabacca, Antonio
Politano, Luisa
Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up
title Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up
title_full Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up
title_fullStr Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up
title_full_unstemmed Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up
title_short Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up
title_sort can symptomatic nmduchenne carriers benefit from treatment with ataluren? results of 193-month follow-up
topic Retraction Statement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299955/
https://www.ncbi.nlm.nih.gov/pubmed/35919205
work_keys_str_mv AT doriamir cansymptomaticnmduchennecarriersbenefitfromtreatmentwithatalurenresultsof193monthfollowup
AT guglierimichela cansymptomaticnmduchennecarriersbenefitfromtreatmentwithatalurenresultsof193monthfollowup
AT scutiferomarianna cansymptomaticnmduchennecarriersbenefitfromtreatmentwithatalurenresultsof193monthfollowup
AT passamanoluigia cansymptomaticnmduchennecarriersbenefitfromtreatmentwithatalurenresultsof193monthfollowup
AT trabaccaantonio cansymptomaticnmduchennecarriersbenefitfromtreatmentwithatalurenresultsof193monthfollowup
AT politanoluisa cansymptomaticnmduchennecarriersbenefitfromtreatmentwithatalurenresultsof193monthfollowup

Ejemplares similares